Clik here to view.
HeartFlow Receives National Reimbursement Approval in Japan
REDWOOD CITY, Calif. HeartFlow, Inc. today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved the recommendation by the Central Social Insurance Medical Council...
View ArticleClik here to view.
術後貧血管理に関する国際的合意声明でMasimo SpHb®を含む非侵襲的ヘモグロビン測定が推奨される
スイス・ヌーシャテル （ビジネスワイヤ） — マシモ（NASDAQ:...
View ArticleClik here to view.
AVITA Medical Announces Hiring of Full U.S. Sales Team of Experienced Burn...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has completed hiring of the U.S. sales team to...
View ArticleClik here to view.
SpinalCyte宣布，注射CybroCell™后，MRI转归可维持12个月
休斯敦 (美国商业资讯) — SpinalCyte, LLC是一家总部位于美国德州的再生医学公司，专注于采用其通用型供体产品CybroCell™再造椎间盘髓核，该公司今天宣布，椎间盘退行性变(DDD)患者接受改性人类皮肤成纤维细胞(HDF)单次注射后12个月，椎间盘高度显著增加、疼痛显著减轻。 该试验采用《Oswestry残疾指数》(Oswestry Disability Index,...
View ArticleClik here to view.
SpinalCyte、CybroCell™注入後のMRI評価が12カ月間にわたり維持されたと発表
ヒューストン （ビジネスワイヤ） — テキサスに拠点を置き、ユニバーサルドナー細胞製品CybroCell™を使用した椎間板髄核再生に傾注する再生医療技術企業のSpinalCyte, LLCは本日、椎間板変性症（DDD）患者で改良ヒト皮膚線維芽細胞（HDF）の単回注入が、細胞治療製品の注入から12カ月後の椎間板高および疼痛緩和の面で顕著な改善につながったと発表しました。...
View ArticleClik here to view.
Stanford Neuroscientist Karl Deisseroth Receives Japan’s Kyoto Prize in...
KYOTO, Japan The Inamori Foundation today announced that it has presented its 34th annual Kyoto Prize in Advanced Technology to Dr. Karl Deisseroth, M.D., Ph.D., a Stanford University neuroscientist...
View ArticleClik here to view.
SANYEI CORPORATION Based in Japan Launches ION-Sei™ into the UK Market in...
DÜSSELDORF, Germany Launching in time for Christmas in UK for people who appreciate holistic health and appreciate great oral care. Providing a stylish and affordable present (RRP 129.99) that also...
View ArticleClik here to view.
CDISC Releases Therapeutic Area User Guide to Bring Clarity to Data for...
AUSTIN, Texas CDISC is pleased to announce the release of a Therapeutic Area (TA) Standard that specifies how to structure data in clinical research studies for Colorectal Cancer. The standard,...
View ArticleClik here to view.
Vineti™ to Partner With Tessa Therapeutics™ to Advance and Scale Cancer...
SAN FRANCISCO Vineti, Inc., the leading digital “platform of record” for personalized therapies, today announced a new partnership with Tessa Therapeutics to advance and scale personalized cell...
View ArticleClik here to view.
Vineti™与Tessa Therapeutics合作在全球推广癌症免疫疗法
旧金山 (美国商业资讯) — Vineti, Inc.是面向个体化疗法的领先的数字“记录平台”，该公司今天宣布与Tessa Therapeutics缔结新的伙伴关系，在亚洲及全球推广实体瘤个体化细胞疗法。 Tessa Therapeutics...
View ArticleClik here to view.
Vineti™がTessa Therapeutics™と提携し、がん免疫療法の前進と世界的な規模拡大を目指す
サンフランシスコ （ビジネスワイヤ） — 個別化治療のためのデジタル「記録プラットフォーム」の大手企業Vineti, Inc.は本日、新たにTessa Therapeuticsと提携関係に入り、固形腫瘍に対する個別化細胞療法のアジアと世界での前進と規模拡大を目指すと発表しました。 Tessa...
View ArticleClik here to view.
Japan-India collaboration yields a novel treatment method for male urethral...
TOKYO A novel and relatively pain-less treatment method for male urethral stricture using patients own buccal mucosal cells has been reported as successful in four out of six patients. The study has...
View ArticleClik here to view.
日印の協業が尿道狭窄の新規治療法を生み出す
東京 （ビジネスワイヤ） — 患者の頬粘膜細胞を使用した男性尿道狭窄の新規治療法として、痛みが比較的少ない方法が患者6人のうち4人で成功したとの報告がなされました。本研究は、日本の生体材料技術の研究者とインドの泌尿器科医のDr Suryaprakash Vaddiの共同研究の成果として、日本泌尿器科学会の公式誌であるInternational Journal of...
View ArticleClik here to view.
European Commission Approves ALUNBRIG® (brigatinib) for ALK+ Non-Small Cell...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Commission (EC) granted marketing authorization for ALUNBRIG (brigatinib) as a...
View ArticleClik here to view.
ImpediMed’s SOZO® Digital Health Platform Voted Among Top Five Finalists for...
BRISBANE, Australia & CARLSBAD, Calif. ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status...
View ArticleClik here to view.
100,000 Rural Children of Maharashtra to Be Screened for Congenital Heart...
MUMBAI, India HD Medical, Inc. of Silicon Valley announces its participation in the large-scale Divine Mother & Child Health Program (DMCHP) cardiac screening study of 100,000 children at Sri...
View ArticleClik here to view.
Dr. Reddy’s Laboratories Announces the Launch of Chlorthalidone Tablets, USP...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the...
View ArticleClik here to view.
Celltrion and Teva Announce FDA Approval of TRUXIMA® (rituximab-abbs), a...
INCHEON, South Korea & JERUSALEM Celltrion, Inc. (KRX:068270) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has...
View ArticleClik here to view.
Visioneering Technologies Inc. Appoints Dr. Peg Achenbach as Vice President,...
ATLANTA To ensure that Eye Care Professionals (ECPs) fully connect with its technology and growing product portfolio, Visioneering Technologies Inc. (VTI), a global company dedicated to improving...
View ArticleClik here to view.
欧盟委员会核准ALUNBRIG® (brigatinib)用于既往接受过克唑替尼治疗的ALK+非小细胞肺癌患者，促进欧洲治疗范式
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE: 4502)今天宣布，欧盟委员会(EC)核准ALUNBRIG...
View Article